Centaurus Financial Inc. Sells 150 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Centaurus Financial Inc. lessened its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 10.7% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,251 shares of the biotechnology company’s stock after selling 150 shares during the quarter. Centaurus Financial Inc.’s holdings in Sarepta Therapeutics were worth $156,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Farallon Capital Management LLC lifted its stake in shares of Sarepta Therapeutics by 102.8% in the 1st quarter. Farallon Capital Management LLC now owns 2,453,500 shares of the biotechnology company’s stock worth $317,630,000 after purchasing an additional 1,243,427 shares during the period. Thrivent Financial for Lutherans lifted its position in shares of Sarepta Therapeutics by 6.3% in the second quarter. Thrivent Financial for Lutherans now owns 644,675 shares of the biotechnology company’s stock valued at $101,858,000 after acquiring an additional 37,940 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Sarepta Therapeutics by 1.2% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 611,749 shares of the biotechnology company’s stock worth $76,401,000 after purchasing an additional 6,992 shares in the last quarter. abrdn plc lifted its holdings in shares of Sarepta Therapeutics by 30.7% in the third quarter. abrdn plc now owns 431,098 shares of the biotechnology company’s stock worth $53,935,000 after buying an additional 101,253 shares in the last quarter. Finally, Mizuho Markets Americas LLC lifted its stake in Sarepta Therapeutics by 22.3% in the 3rd quarter. Mizuho Markets Americas LLC now owns 399,065 shares of the biotechnology company’s stock worth $49,839,000 after purchasing an additional 72,765 shares in the last quarter. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Insider Buying and Selling at Sarepta Therapeutics

In other news, CFO Ian Michael Estepan sold 5,985 shares of the business’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $137.36, for a total transaction of $822,099.60. Following the sale, the chief financial officer now directly owns 33,946 shares of the company’s stock, valued at $4,662,822.56. The trade was a 14.99 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 7.70% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several research firms have commented on SRPT. Barclays lowered their price objective on shares of Sarepta Therapeutics from $226.00 to $203.00 and set an “overweight” rating for the company in a research report on Thursday, August 8th. StockNews.com cut Sarepta Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, November 20th. Piper Sandler cut their price objective on Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating on the stock in a research report on Wednesday. Raymond James reiterated an “outperform” rating and set a $150.00 target price on shares of Sarepta Therapeutics in a research report on Thursday, October 10th. Finally, Guggenheim upped their target price on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, twenty have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Sarepta Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $175.77.

Sarepta Therapeutics Stock Performance

Shares of SRPT stock opened at $137.94 on Thursday. Sarepta Therapeutics, Inc. has a 12-month low of $78.67 and a 12-month high of $173.25. The business’s fifty day simple moving average is $121.90 and its 200-day simple moving average is $131.39. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The company has a market cap of $13.18 billion, a PE ratio of 110.35 and a beta of 0.81.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.